Literature DB >> 1577056

Theophylline steady state pharmacokinetics is not altered by omeprazole.

A M Taburet1, J Geneve, M Bocquentin, G Simoneau, C Caulin, E Singlas.   

Abstract

The effect of omeprazole treatment on theophylline pharmacokinetics was studied in eight, non-smoking healthy male volunteers during repeated administration of a slow release formulation of theophylline. In a randomized double-blind cross-over study, the subjects received theophylline 5 mg.kg-1 per day with omeprazole 20 mg per day or identical placebo during two periods, each of 7 days, separated by a washout period of 7 days. The oral clearance of theophylline remained unchanged whether it was administered alone or with omeprazole (54.2 ml.min-1). The average urinary excretion of theophylline and its metabolites, 1,3 dimethyluric acid (1,3-DMU), 3-methylxanthine (3-MX), 1-methyluric acid (1-MU) amounted to 9%, 32%, 12% and 22% of the administered dose, respectively, and no significant change occurred during concomitant treatment with omeprazole. Thus, the formation and clearance of the metabolites was not altered by omeprazole. Consequently, omeprazole in the recommended dose of 20 mg daily can safely be administered to patients on theophylline therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1577056     DOI: 10.1007/bf00266361

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  Lack of effect of omeprazole treatment on steady-state plasma levels of metoprolol.

Authors:  T Andersson; P Lundborg; C G Regårdh
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Drugs other than H2-receptor antagonists as clinically important inhibitors of drug metabolism in vivo.

Authors:  R Gugler; J C Jensen
Journal:  Pharmacol Ther       Date:  1987       Impact factor: 12.310

3.  A study of the interaction between omeprazole and phenytoin in epileptic patients.

Authors:  T Andersson; P O Lagerström; P Unge
Journal:  Ther Drug Monit       Date:  1990-07       Impact factor: 3.681

Review 4.  Drug metabolite kinetics.

Authors:  J B Houston
Journal:  Pharmacol Ther       Date:  1981       Impact factor: 12.310

5.  Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450.

Authors:  D Diaz; I Fabre; M Daujat; B Saint Aubert; P Bories; H Michel; P Maurel
Journal:  Gastroenterology       Date:  1990-09       Impact factor: 22.682

Review 6.  A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.

Authors:  L Hendeles; R P Iafrate; M Weinberger
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

7.  In vitro effect of fluoroquinolones on theophylline metabolism in human liver microsomes.

Authors:  M Sarkar; R E Polk; P S Guzelian; C Hunt; H T Karnes
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

8.  Characterisation of theophylline metabolism by human liver microsomes. Inhibition and immunochemical studies.

Authors:  R A Robson; J O Miners; A P Matthews; I Stupans; D Meller; M E McManus; D J Birkett
Journal:  Biochem Pharmacol       Date:  1988-05-01       Impact factor: 5.858

9.  Determination of theophylline and its metabolites in plasma and urine by reversed-phase liquid chromatography using an amine modifier.

Authors:  E Naline; B Flouvat; C Advenier; M Pays
Journal:  J Chromatogr       Date:  1987-08-07

10.  Propranolol steady-state pharmacokinetics are unaltered by omeprazole.

Authors:  D Henry; P Brent; I Whyte; G Mihaly; S Devenish-Meares
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

View more
  14 in total

Review 1.  Pharmacokinetic drug interaction profiles of proton pump inhibitors.

Authors:  Henning Blume; Frank Donath; André Warnke; Barbara S Schug
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 2.  Pharmacokinetic considerations in the eradication of Helicobacter pylori.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 3.  Pharmacokinetic drug interactions with anti-ulcer drugs.

Authors:  R D Negro
Journal:  Clin Pharmacokinet       Date:  1998-08       Impact factor: 6.447

Review 4.  Clinically significant pharmacokinetic interactions between dietary caffeine and medications.

Authors:  J A Carrillo; J Benitez
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

Review 5.  Drug interactions with proton pump inhibitors.

Authors:  P Unge; T Andersson
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

6.  Omeprazole and lansoprazole are not inducers of cytochrome P4501A2 under conventional therapeutic conditions.

Authors:  N Rizzo; C Padoin; S Palombo; J M Scherrmann; C Girre
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 7.  Drug-drug interaction profiles of proton pump inhibitors.

Authors:  Ryuichi Ogawa; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2010-08       Impact factor: 6.447

Review 8.  Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.

Authors:  U Tröger; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

Review 9.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 10.  Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.